Form 4 for ARWR ARROWHEAD PHARMACEUTICALS, INC.
Accepted 2023-01-05 00:00:00 ET · period of report 2023-01-04 · accession 0001209191-23-002116 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-01-05 | 2023-01-04 | ARWR | Myszkowski Kenneth Allen | CFO | A - Grant | $0.00 | +60.0K | 396.7K | +18% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-04 | A | A | 60,000 | $0.00 | 396,704 | D | — | — | (F1) Represents shares underlying a restricted stock unit, which shares will vest in four equal annual installments, with a commencement date of 1/4/23. (F2) Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. |